These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19040203)

  • 1. In vivo (1)H MRS of WSU-DLCL2 human non-Hodgkin's lymphoma xenografts: response to rituximab and rituximab plus CHOP.
    Lee SC; Delikatny EJ; Poptani H; Pickup S; Glickson JD
    NMR Biomed; 2009 Apr; 22(3):259-65. PubMed ID: 19040203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft.
    Lee SC; Huang MQ; Nelson DS; Pickup S; Wehrli S; Adegbola O; Poptani H; Delikatny EJ; Glickson JD
    NMR Biomed; 2008 Aug; 21(7):723-33. PubMed ID: 18384181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMR metabolic and physiological markers of therapeutic response.
    Lee SC; Poptani H; Delikatny EJ; Pickup S; Nelson DS; Schuster SJ; Nasta SD; Svoboda J; Goldstein SC; Wallace SG; Loevner LA; Mellon EA; Reddy R; Glickson JD
    Adv Exp Med Biol; 2011; 701():129-35. PubMed ID: 21445779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of radiation therapy response in non-Hodgkin's lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging.
    Lee SC; Poptani H; Pickup S; Jenkins WT; Kim S; Koch CJ; Delikatny EJ; Glickson JD
    NMR Biomed; 2010 Jul; 23(6):624-32. PubMed ID: 20661875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
    J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS.
    Huang MQ; Nelson DS; Pickup S; Qiao H; Delikatny EJ; Poptani H; Glickson JD
    Acad Radiol; 2007 Dec; 14(12):1531-9. PubMed ID: 18035282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
    Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.
    Mohammad RM; Al-Katib A; Aboukameel A; Doerge DR; Sarkar F; Kucuk O
    Mol Cancer Ther; 2003 Dec; 2(12):1361-8. PubMed ID: 14707277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
    Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W
    Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
    Hainsworth JD; Litchy S; Lamb MR; Rodriguez GI; Scroggin C; Greco FA
    Clin Lymphoma; 2003 Jun; 4(1):36-42. PubMed ID: 12837153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
    Fanale MA; Younes A
    Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma.
    Herrmann K; Wieder HA; Buck AK; Schöffel M; Krause BJ; Fend F; Schuster T; Meyer zum Büschenfelde C; Wester HJ; Duyster J; Peschel C; Schwaiger M; Dechow T
    Clin Cancer Res; 2007 Jun; 13(12):3552-8. PubMed ID: 17575218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunochemotherapy in indolent non-Hodgkin's lymphoma.
    Czuczman MS
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):11-7. PubMed ID: 12040529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.
    Ackler S; Mitten MJ; Chen J; Clarin J; Foster K; Jin S; Phillips DC; Schlessinger S; Wang B; Leverson JD; Boghaert ER
    Br J Pharmacol; 2012 Oct; 167(4):881-91. PubMed ID: 22624727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck.
    Manolopoulos L; Gomatos IP; Leandros E; Alevizos L; Georgiou N; Giotakis J; Ferekidis E
    In Vivo; 2009; 23(3):475-8. PubMed ID: 19454517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
    Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
    Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.